Patient-derived Xenografts (PDXs) are considered as relevant preclinical model for anticancer drug development due to original recapitulation of patient genetic profile, gene expression patterns and tissue histology. In this study, we investigated combination efficacy of CDODA-Me (Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate) and TKI inhibitor Erlotinib (ERL) against Lung NSCLC PDX spheroids and 3D bioprinted PDX cells.
This review focuses on developments in the field of bioprinting for musculoskeletal tissue engineering, along with discussion on the various approaches for bone, cartilage and connective tissue fabrication. All approaches (cell-laden, cell-free and a combination of both) aim to obtain complex, living tissues able to develop and mature, using the same fundamental technology.
Our Cellink Diamond Partners are hand selected by us in order to achieve well rounded and synergical partnerships in the life science industry.
Are you interested in becoming a Diamond Partner? Please fill in the application form below.
Complete the application form if you want to apply for partnership. Name and E-mail fields are mandatory.